Literature DB >> 15858125

High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma.

R Rust1, G Harms, T Blokzijl, M Boot, A Diepstra, J Kluiver, L Visser, S-C Peh, M Lim, W A Kamps, S Poppema, A van den Berg.   

Abstract

AIM: To gain more insight into the genes involved in the aetiology and pathogenesis of anaplastic large cell lymphoma (ALCL).
METHODS: Serial analysis of gene expression (SAGE) was undertaken on the CD4+ALK+ (anaplastic lymphoma kinase positive) ALCL derived cell line Karpas299 and as comparison on CD4+ T cells. Quantitative reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry were performed on five ALCL derived cell lines and 32 tissue samples to confirm the SAGE data.
RESULTS: High expression of Mcl-1 was seen in the Karpas299 cell line, whereas the two other antiapoptotic Bcl-2 family members, Bcl-2 and Bcl-X(L), were not detected in the SAGE library. Quantitative RT-PCR confirmed the high expression of Mcl-1 mRNA and low expression of Bcl-2 and Bcl-X(L) in Karpas299 and in four other ALCL cell lines. To expand on these initial observations, primary tissue samples were analysed for Mcl-1, Bcl-X(L), and Bcl-2 by immunohistochemistry. All 23 ALK+ and nine ALK- ALCL cases were positive for Mcl-1. Bcl-2 and Bcl-X(L) were expressed infrequently in ALK+ ALCL cases, but were present in a higher proportion of ALK- ALCL cases.
CONCLUSION: The consistent high expression of Mcl-1 in ALK+ and ALK- ALCL suggests that Mcl-1 is the main antiapoptotic protein in this disease. The high frequency of Mcl-1, Bcl-2, and Bcl-X(L) positive ALCL cases in the ALK- group compared with the ALK+ group indicates that ALK induced STAT3 activation is not the main regulatory pathway in ALCL.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15858125      PMCID: PMC1770666          DOI: 10.1136/jcp.2004.022335

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  42 in total

1.  High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma.

Authors:  A van den Berg; L Visser; S Poppema
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

2.  Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors.

Authors:  George Z Rassidakis; Raymond Lai; Timothy J McDonnell; Fernando Cabanillas; Andreas H Sarris; L Jeffrey Medeiros
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

Review 3.  Life-or-death decisions by the Bcl-2 protein family.

Authors:  J M Adams; S Cory
Journal:  Trends Biochem Sci       Date:  2001-01       Impact factor: 13.807

4.  The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway.

Authors:  L H Wei; M L Kuo; C A Chen; C H Chou; W F Cheng; M C Chang; J L Su; C Y Hsieh
Journal:  Oncogene       Date:  2001-09-13       Impact factor: 9.867

5.  Gene profiling in anaplastic large-cell lymphoma-derived cell lines with cDNA expression arrays.

Authors:  Timo Gaiser; Christoph Thorns; Hartmut Merz; Frank Noack; Alfred C Feller; Karin Lange
Journal:  J Hematother Stem Cell Res       Date:  2002-04

6.  Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage.

Authors:  G Z Rassidakis; A H Sarris; M Herling; R J Ford; F Cabanillas; T J McDonnell; L J Medeiros
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

7.  MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes.

Authors:  P Zhou; N B Levy; H Xie; L Qian; C Y Lee; R D Gascoyne; R W Craig
Journal:  Blood       Date:  2001-06-15       Impact factor: 22.113

8.  Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death.

Authors:  Alberto Zamo; Roberto Chiarle; Roberto Piva; Jennifer Howes; Yan Fan; Marco Chilosi; David E Levy; Giorgio Inghirami
Journal:  Oncogene       Date:  2002-02-07       Impact factor: 9.867

Review 9.  Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.

Authors:  Ralf Buettner; Linda B Mora; Richard Jove
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

Review 10.  MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis.

Authors:  R W Craig
Journal:  Leukemia       Date:  2002-04       Impact factor: 11.528

View more
  9 in total

1.  Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis.

Authors:  Tri K Nguyen; Nicholas Jordan; Jonathan Friedberg; Richard I Fisher; Paul Dent; Steven Grant
Journal:  Leuk Res       Date:  2010-02-01       Impact factor: 3.156

2.  Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.

Authors:  Roberto Piva; Elisa Pellegrino; Michela Mattioli; Luca Agnelli; Luigia Lombardi; Francesco Boccalatte; Giulia Costa; Bruce A Ruggeri; Mangeng Cheng; Roberto Chiarle; Giorgio Palestro; Antonino Neri; Giorgio Inghirami
Journal:  J Clin Invest       Date:  2006-11-16       Impact factor: 14.808

Review 3.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

4.  An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737.

Authors:  Sayer Al-Harbi; Brian T Hill; Suparna Mazumder; Kamini Singh; Jennifer Devecchio; Gaurav Choudhary; Lisa A Rybicki; Matt Kalaycio; Jaroslaw P Maciejewski; Janet A Houghton; Alexandru Almasan
Journal:  Blood       Date:  2011-07-19       Impact factor: 22.113

Review 5.  Survival control of malignant lymphocytes by anti-apoptotic MCL-1.

Authors:  Y Fernández-Marrero; S Spinner; T Kaufmann; P J Jost
Journal:  Leukemia       Date:  2016-08-01       Impact factor: 11.528

6.  Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK(+) anaplastic large cell lymphoma.

Authors:  Farid Saei Hamedani; Munevver Cinar; Zhicheng Mo; Melissa A Cervania; Hesham M Amin; Serhan Alkan
Journal:  Leuk Res       Date:  2014-01-08       Impact factor: 3.156

7.  Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death.

Authors:  Avedis Torossian; Nicolas Broin; Julie Frentzel; Camille Daugrois; Sarah Gandarillas; Talal Al Saati; Laurence Lamant; Pierre Brousset; Sylvie Giuriato; Estelle Espinos
Journal:  Haematologica       Date:  2019-01-24       Impact factor: 9.941

Review 8.  The Dual Role of Autophagy in Crizotinib-Treated ALK+ ALCL: From the Lymphoma Cells Drug Resistance to Their Demise.

Authors:  Estelle Espinos; Raymond Lai; Sylvie Giuriato
Journal:  Cells       Date:  2021-09-23       Impact factor: 6.600

9.  Inhibition of MCL1 induces apoptosis in anaplastic large cell lymphoma and in primary effusion lymphoma.

Authors:  Hilmar Quentmeier; Robert Geffers; Vivien Hauer; Stefan Nagel; Claudia Pommerenke; Cord C Uphoff; Margarete Zaborski; Hans G Drexler
Journal:  Sci Rep       Date:  2022-01-20       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.